Sahajanand Medical Technologies, commonly known as SMT, is an India-based medical technology company specializing in cardiovascular, endovascular and structural-heart devices. The company develops and manufactures minimally invasive technologies used in interventional cardiology and vascular procedures.

Founded in 2001, SMT has grown from a company focused on coronary stent technology into a broader cardiovascular medical-device manufacturer. Its portfolio includes coronary stents, PTCA balloon catheters, peripheral vascular devices, structural-heart technologies, occluders, TAVI systems and other interventional products.

The company has research and development operations in India and internationally and reports a presence in more than 80 countries.

About Sahajanand Medical Technologies

Sahajanand Medical Technologies was established in 2001 with a focus on developing cardiovascular medical devices.

Over the years, the company has expanded its technology portfolio across several areas of minimally invasive cardiovascular treatment.

Its major areas include:

• Coronary intervention
• Peripheral vascular intervention
• Structural heart intervention
• Cardiac closure devices
• TAVI/TAVR
• Balloon catheter technology
• Endovascular intervention
• Vascular access and related accessories

SMT describes its mission as “Pledged to Save Millions” and focuses on clinically supported technologies for complex cardiovascular procedures.

Major Products Manufactured by SMT

1. Coronary Stents

Coronary stents are one of SMT’s best-known product categories.

A coronary stent is a small expandable mesh-like medical device placed inside a narrowed coronary artery to help maintain blood flow after an angioplasty procedure.

SMT manufactures several coronary stent systems, including drug-eluting stent technologies.

Its product development history includes the Supralimus, Supraflex and Tetrilimus families. The company’s journey page records CE approvals for its coronary stent systems and later product launches including Tetrilimus and Supraflex-related technologies.

Drug-Eluting Stents

Drug-eluting stents combine a metallic stent platform with a drug-containing coating.

The drug is released locally after implantation and is intended to reduce excessive tissue growth inside the treated artery.

SMT has developed drug-eluting coronary stents using different platforms and polymer technologies.

The company was also among the early manufacturers to obtain CE certification for a drug-eluting stent using a biodegradable polymer.

2. Supraflex Coronary Stent Family

The Supraflex family represents an important part of SMT’s coronary-intervention portfolio.

SMT’s product-development history records CE approval for Supraflex in 2013. Later developments expanded the company’s coronary stent portfolio.

The Supraflex platform has been developed for use in percutaneous coronary intervention, where physicians treat narrowed or blocked coronary arteries using catheter-based techniques.

3. Tetrilimus Coronary Stent

Tetrilimus is another coronary drug-eluting stent system developed by SMT.

SMT’s product-development history records the launch of Tetrilimus in 2015 as an everolimus-eluting cobalt-chromium coronary stent system.

Cobalt-chromium alloys are used in many modern stent platforms because they can provide the required mechanical properties while allowing relatively thin stent structures.

4. PTCA Balloon Catheters

Balloon catheters are essential devices used during angioplasty and other catheter-based vascular procedures.

PTCA stands for Percutaneous Transluminal Coronary Angioplasty.

A PTCA balloon catheter is advanced through the vascular system to the target lesion. The balloon can then be inflated to help expand a narrowed coronary artery or prepare the lesion for stent placement.

SMT manufactures multiple balloon-catheter technologies.

Its product-development history lists the Wilma PTCA Dilatation Catheter, while the current portfolio includes balloon systems such as Pipit SC and Pipit NC.

5. Semi-Compliant Balloon Catheters

Semi-compliant balloons are designed to expand in a controlled manner when inflated.

SMT’s Pipit SC is a semi-compliant balloon catheter platform used in coronary intervention.

These devices can be used for lesion preparation and balloon angioplasty according to the specific clinical situation.

6. Non-Compliant Balloon Catheters

Non-compliant balloons are designed to maintain their shape and diameter more consistently at higher inflation pressures.

SMT’s Pipit NC belongs to this category.

High-pressure non-compliant balloons can be used for post-dilatation and other selected coronary-intervention applications where precise balloon expansion is required.

SMT has highlighted both Pipit SC and Pipit NC among its cardiovascular technologies.

Peripheral Vascular Intervention

SMT has expanded beyond coronary intervention into peripheral vascular treatment.

Peripheral vascular intervention involves catheter-based treatment of blood vessels outside the coronary arteries, including vessels supplying the legs and other parts of the body.

7. Peripheral Angioplasty Balloons

SMT’s Peripherics balloon platform is designed for peripheral transluminal angioplasty applications.

The company lists over-the-wire balloon configurations for below-the-knee and superficial femoral artery applications. Its published specifications include different balloon diameters and lengths for these vascular territories.

Peripheral balloons may be used to dilate narrowed peripheral blood vessels during minimally invasive procedures.

8. Peripheral Stents

SMT’s broader vascular portfolio includes peripheral stent technologies.

Peripheral stents are designed to help maintain vessel patency after treatment of certain arterial blockages.

The company’s portfolio has expanded from coronary devices into peripheral and endovascular intervention.

9. Renal and Biliary Stents

SMT’s historical product portfolio also includes renal and biliary stent systems.

The company’s 2015 product-development history records the launch of Renofit, a balloon-expandable cobalt-chromium renal and biliary stent system.

These technologies demonstrate SMT’s broader interest in catheter-based intervention beyond coronary arteries.

Structural Heart Technologies

Structural heart disease involves abnormalities of the heart’s valves or structures separating the chambers of the heart.

SMT has expanded into this field with transcatheter valve and closure technologies.

10. Hydra TAVI System

One of SMT’s major structural-heart technologies is the Hydra TAVI/TAVR system.

TAVI stands for Transcatheter Aortic Valve Implantation, while TAVR is the commonly used term for transcatheter aortic valve replacement.

The procedure allows a replacement aortic valve to be delivered through a catheter rather than requiring conventional open-heart valve replacement in suitable patients.

SMT’s Hydra system is described as a self-expanding transcatheter aortic valve with features including re-sheathing, repositioning and retrieval during deployment.

The Technology Development Board of India’s Department of Science & Technology has also identified SMT’s TAVI product-enhancement and commercialization project.

11. Cardiac Closure Devices

SMT also develops occluders used to close selected abnormal openings in the heart or associated structures.

These devices can be used in catheter-based procedures for congenital heart defects.

SMT identifies occluders for congenital defects as one of its core structural-heart technologies.

12. Cocoon Occluders

The Cocoon platform is part of SMT’s structural-heart portfolio.

SMT’s product portfolio includes Cocoon occluders for different closure applications, including devices associated with septal and other congenital defects.

Catheter-based occluder systems can allow physicians to treat selected defects without conventional open-heart surgery.

Other Cardiovascular Technologies

13. Aspiration and Endovascular Devices

SMT has expanded its portfolio into endovascular intervention.

Its current cardiovascular offering includes technologies for catheter-based treatment of vascular conditions.

The company’s broader portfolio has been described as covering coronary, peripheral and structural-heart intervention.

14. Vascular and Cardiac Accessories

Cardiovascular procedures require multiple supporting devices in addition to the primary implant.

SMT’s portfolio includes various accessories and catheter-based technologies used during interventional procedures.

These can include delivery systems, catheter components and other products needed to navigate and treat blood vessels.

Research and Development

Research and development is an important part of SMT’s business.

The company operates R&D facilities in Surat, India; Galway, Ireland; and Nonthaburi, Thailand, according to India’s Technology Development Board.

SMT also states that it works on clinical development and evidence generation for its cardiovascular technologies.

Its product technologies have been evaluated through clinical studies, registries and other forms of clinical evidence.

Innovation in Coronary Stent Technology

SMT has invested significantly in stent-platform development.

Its development history shows a progression from early coronary stent systems to drug-eluting stents, biodegradable-polymer technologies and newer-generation coronary platforms.

This development has helped SMT build expertise in:

• Stent design
• Drug-delivery coatings
• Polymer technology
• Balloon delivery systems
• Catheter engineering
• Minimally invasive cardiovascular procedures

Global Presence

SMT has developed an international presence beyond India.

The company states that it has a presence in more than 80 countries, while an Indian industry compendium reported footprints in more than 75 countries as of March 31, 2025.

Its international activities include cardiovascular-device manufacturing, research, clinical development and distribution.

The company therefore represents one of India’s medical-device manufacturers with a substantial international focus.

Manufacturing and Medical Technology

SMT’s operations combine product design, research, manufacturing and clinical development.

The company has manufacturing facilities and research operations supporting its cardiovascular and structural-heart portfolio.

Its product-development strategy focuses particularly on minimally invasive procedures, where devices must be delivered through relatively small vascular access routes and positioned accurately at the treatment site.

SMT’s Importance in India’s Medical-Device Industry

Sahajanand Medical Technologies is notable because it operates in a highly specialised area of medical-device manufacturing.

Instead of focusing primarily on basic hospital consumables, SMT concentrates heavily on sophisticated cardiovascular technologies such as:

• Coronary drug-eluting stents
• PTCA balloon catheters
• Peripheral vascular devices
• Structural-heart devices
• TAVI systems
• Cardiac occluders
• Endovascular intervention products

The company’s development demonstrates the growth of India’s domestic capability in high-end interventional cardiology and structural-heart technology.

Frequently Asked Questions

Is Sahajanand Medical Technologies an Indian company?

Yes. Sahajanand Medical Technologies is an India-based medical-technology company. It was incorporated in 2001 and is based in Surat, Gujarat.

What does Sahajanand Medical Technologies manufacture?

SMT manufactures and develops cardiovascular and minimally invasive medical devices, including coronary stents, balloon catheters, peripheral vascular devices, cardiac closure devices and structural-heart technologies.

Does SMT manufacture coronary stents?

Yes. Coronary stents are one of SMT’s principal product categories. Its portfolio includes technologies such as Supraflex and Tetrilimus.

Does SMT manufacture balloon catheters?

Yes. SMT manufactures PTCA balloon catheters and peripheral angioplasty balloon systems. Products include Pipit SC, Pipit NC and Peripherics.

What is the Hydra TAVI system?

Hydra is SMT’s self-expanding transcatheter aortic valve system. It is designed for transcatheter aortic valve implantation/replacement and includes features intended to allow repositioning and retrieval during deployment.

Does SMT manufacture cardiac closure devices?

Yes. SMT develops occluder devices for selected congenital heart defects and structural-heart applications. Its Cocoon platform is one of its closure-device technologies.

Where is Sahajanand Medical Technologies located?

SMT was incorporated and operates from Surat, Gujarat, India. The company also has international research and business operations.

In how many countries does SMT operate?

SMT states that it has a presence in more than 80 countries.

Conclusion

Sahajanand Medical Technologies has developed from an Indian coronary-device company into a broader medical-technology organisation focused on cardiovascular, endovascular and structural-heart interventions.

Its product portfolio includes coronary drug-eluting stents, PTCA balloon catheters, peripheral vascular balloons and stents, cardiac closure devices and advanced structural-heart technologies such as the Hydra TAVI system.

The company’s emphasis on minimally invasive cardiovascular treatment, research and clinical development makes it an important participant in India’s growing medical-device industry.

With manufacturing and R&D capabilities in India and international operations across multiple markets, SMT demonstrates how Indian medical-device companies are developing sophisticated technologies for interventional cardiology and structural-heart care.